Member Info for BBB11

Signing off the board until the New Year.

Proud to be invested alongside people backing something far bigger than a share price. What we’re supporting has the potential to genuinely change and save lives, especially for the children and patients facing AML with limited options.

Here’s to 2026 being the year our belief in HEMO turns into real impact for those, who today, are unsure whether they will see another Christmas and where our investment makes it a possibility that they will.

Wishing all HEMO investors a very Merry Christmas.

I don’t doubt Vlad has been approached by brokers or that there are supportive long-term holders involved.

My view is simply that £190k on its own isn’t a strategic funding decision. If a better deal had been on the table at that point, it would have been taken to secure longer-term runway.

I’m heavily invested and, realistically, I expect a slightly discounted placing in the £5m–£10m range for 9-12 months runway. The cash generating ideas, such as renting out space or the Estonia route, are likely to take longer than I initially thought. Once funding is secured, however, the company can move forward positively without near-term cashflow concerns, and that’s when the real milestones come into play, which could take the SP well above current levels.

This is just my opinion. So far, I’ve not seen any funding that hasn’t been discounted unless it was directly tied to purchasing a product from the company providing the capital. I’d be very happy to see that change.

Funding, even at a slight discount, is normal for early-stage biotech. What matters is getting the pipeline moving again, as that’s where the real ROI sits...

I’ve taken a lot of your input on board over the past few years, so I hope you’re right on this. I’m just being honest about what I expect as a retail investor, based on what I can see today. Still incredibly bullish on HEMO doing well..

Hereforhemo, I like the bullish mentality.

That said, I’ve never known any company, especially one in HEMO’s position, to refuse funding if it was genuinely on the table. When a company has clearly stated it needs to raise, turning down meaningful capital just doesn’t make sense.

For that reason, I don’t believe the £190k raise was “strategic” in isolation. It’s far more likely that a larger funding package is already being arranged, and the £190k was simply what they needed or were willing to take at that stage, possibly as a bridge, before deeper pockets come in.

Boards don’t gamble with survival to make a point. They manage timing, structure, and optics. To me, this looks less like refusal of funding and more like sequencing of funding.

If a proper runway raise lands in January, the £190k will make sense in hindsight as a small step in a bigger plan, not the plan itself for a deal etc.

Q1 2026 key milestones

HG-CT-1 adults, first patient dosed at higher level and a clean 28-day safety window.

Paediatrics, cohort is approved and ready, real SP increase is confirmation of first child enrolled and dosed. Biggest near-term RNS for big SP spike.

Manufacturing, Made Scientific tech transfer and qualification runs fully signed off so patients can be treated without delay.

Funding, company requires a funding event before March 2026, but the structure matters more than size. I believe a 9–12 month funding package is likely in January, which should lift sentiment and SP by removing the overhang.

H1 2026

Estonia Cellin route, needs a binding agreement and regulatory clarity.

Efficacy, any positive signal during dose escalation would materially strengthen the product story.

CBR platform, only becomes relevant if partnered or monetised, otherwise remains longer-term upside.

CDX asset, requires a funded partner to re-enter the picture, otherwise it stays on the back burner.

My expectation is we see the following:

RNS of made transfer completed. Mid Jan

RNS of funding 9-12 months - end of Jan

RNS of higher dose adult patient - Feb

RNS of peadatrics patient - Feb/March

RNS of Estonia deal - March/April

JPM is the principal and premium global healthcare investor event, bigger and more capital-markets focused than conferences like DCNY which is science/networking focussed.

Attendance puts a company in front of the largest pool of global biotech investors and partnering decision-makers in the world, not just new scientific peers.

So not a good comparison for whoever would say DCNY is better for investment then JPM.

Vlad has confirmed on LinkedIn that he is attending the J.P. Morgan Healthcare Conference 2026 (12–15 Jan).

JPM is where biotech funding, licensing and strategic partnerships actually happen, especially for clinical-stage oncology assets.

Worth clarifying today’s RNS before bad actors make it seem misunderstood.

This was not a discounted placing. The £1.80 shares are from existing warrants being exercised, with the price fixed when those warrants were issued previously. That means fresh cash coming into the company.

In total, around £295k of cash was raised: ~£190k from warrant exercise / ~£105k from variation shares at £8.84. RSUs are non cash and immaterial

Warrant holders choosing to exercise now is a bullish signal, they’re putting new money in ahead of clinical progress.

This is a nice vote of confidence

If you have retained profit in your company as a director you can invest it as you wish as long as it doesn't put the company at risk. It's a very normal process for companies with significant retained earnings to do

So to summarise, you spend hours of your day, every day, firing off pessimistic “corrections” at other people’s opinions, most of whom are actually invested here and have put real money at risk. Yet you still won’t answer the simplest question: is your own money on HEMO going up or down?

If you genuinely “don’t invest emotionally” as you claim, then it should be very easy to state your position and time frame. Are you long, short, or not even holding a single share? Because right now it looks a lot less like neutral “fact checking” and a lot more like someone with an undisclosed book, camping on one small cap board and trying to manage sentiment while pretending they are just here for the science.

Who has access to the WhatsApp group and can share an invite to it?

Saint

Today’s drop is pure sentiment. The company didn’t raise at £10+ because at the time they expected the new agreement to be signed quickly and the initial payment to land well before now. That income was part of the planned runway from August to February. Since we’ve had no RNS on the agreement, ASH submission, or special status, the share price hasn’t had the catalysts needed to hold recent levels. Nothing has changed scientifically, only the timing of expected news.

If the agreement payment slips into the new year, they will need to raise, and honestly it makes sense to do it before year end to strengthen the runway and enter 2026 clean. Panic today is retail seeing silence and assuming the worst, but the fundamentals and pipeline remain intact. The issue is timing, not the scientific trajectory. Not what shareholders want, but we are still 3X a few months ago.

It's a long term investment not a trade. This is biotech - so it's a risk to reward. It can jump 400% in a week, or lose 50% in a week. It's done this for years, it's never nice. Anyone else got a crypto portfolio? Biotech and crypto are the same type of traders or buy / sell / invest IMO.

Likely will be an RNS tomorrow given this, probably a placement, but that's to be expected. Let's just hope it's at a good price.

Holding for gold... Shut off watching your shares for a while and let them go up in the background.

This is not going to £5 Alde. We've all got skin in the game. If you truly believe that please for all our sakes, sell out, shut up, wait, and come back and buy in and gloat. Honestly, in the meantime, please stop talking like you're the 2nd coming of Jesus and all knowing.

The truth is simple - the News is taking longer then we all would have liked, but the utter crap you're writing is a joke. The several bits of news we are expecting are all significant, and I know people with a pretty penny waiting to buy in when it's released and if the news is as expected.

Notposting at this point I believe must be paid to write the amount of utter rubbish he is spitting... The level of pettiness is beyond belief.

Do us all a favour and find another board to annoy and add zero value to.

Nothing in this world can take the place of persistence. Talent will not; nothing is more common than unsuccessful men with talent. Genius will not; unrewarded genius is almost a proverb. Education will not; the world is full of educated derelicts. Persistence and determination alone are omnipotent. The slogan 'Press On!' has solved and always will solve the problems of the human race.

— Calvin Coolidge

12% increase on only £45k buys is pretty nuts

The warrant seller drove this down ridiculously.

Interesting week ahead, let's hope it's in the right direction, but feeling better today about Hemo then I have for a few weeks.

Interesting video from Vox with Vlad.

He seems focused on getting the CAR-T licensed and feels confident about the results, though understandably cautious regarding potential toxicity as doses increase in the adult cohort. 3 cohorts, with ideally 18 patients total is the target. 2 patients a month (1 adult / 1 paediatric) after the 'made scientific' tech transfer.

£2.2m raised and a “significant reduction in burn rate”, we all could see it, but it’s good to hear it confirmed directly from him.

No concrete timelines yet on the tech transfer or Estonia deal, but he sounded positive overall. A good revenue stream, just depends how quickly he can get it up and running.

I get the sense he wants the CAR-T buyout or licence, some can progress the other programmes and keep things intellectually engaging, with a mind like his, he’ll always need to feel he’s moving forward.

The way he discussed funding in a less dilutive way is a big positive compared to previous updates, and it was great to hear him thank investors directly, something many of us had encouraged him to do more of in past years

I believe your investment advice is the right thing to do; doing that level of research is absolutely the right approach. However, most retail investors don’t operate that way; again, 90% of this company is held by them. Your goal to educate people is fair enough, but when it comes at the expense of sentiment and overall confidence in the company, that’s another matter entirely.

Many of us, myself included at times, have overinvested in Hemogenyx while waiting for RNS updates that didn’t materialise. I’ve been here for five years. A lot of investors in this stock are financially overextended, and that inevitably affects their emotional state, so yes, they will get defensive.

If you’re still invested, then your £30k remaining holding is now worth about £15k. I assume you have no emotional attachment to that money? If you did, and believe that no sentiment on this board (As you and NotPosting are by far the biggest posters) why waste your time, and not instead use that drive, motivation and knowledge to communicate with Vlad via email, LinkedIn, mail or telephone?

This company is held by retail traders, not professionals or institutions. 100% what is said on here affects the price. That is why, when there are large short positions, individuals come and deramp; it does have an effect. I know individuals on this board who have bought or sold based on overall sentiment. This is a biotech stock, built on results we have to speculate on, not a financial earnings report of Walmart.

I believe that it is a more likely then not, that there will be another RNS this afternoon.

Yeah, but the amount of money in that room is quite incredible for a local Boston event. CEO's of big pharma and very large investment funds etc.